Literature DB >> 22404554

Current information on the immunologic status of occult hepatitis B infection.

Mohammad Kazemi Arababadi1, Behzad Nasiri Ahmadabadi, Derek Kennedy.   

Abstract

Hepatitis B is one of the most frequently occurring posttransfusion infections. Occult hepatitis B (OB) is a form of hepatitis B in which, despite the presence of hepatitis B virus (HBV) DNA in the serum and hepatocytes of a carrier, hepatitis B surface antigen is absent. In addition to the risk of transfusion of infection, OB can lead to cirrhosis, hepatic cancer, and reactivation of the viral duplication process in the carrier. The mechanisms responsible for progression of OB are yet to be clarified; however, some investigators have suggested that genetic and immunologic variables may play a significant role in the resistance of some individuals and sensitivity of other patients. This review addresses the current information regarding immunologic status of OB-infected patients.
© 2012 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22404554     DOI: 10.1111/j.1537-2995.2012.03575.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  17 in total

Review 1.  Significant roles played by IL-10 in Chlamydia infections.

Authors:  Hamid Hakimi; Mohammad Zare-Bidaki; Nahid Zainodini; Shokrollah Assar; Mohammad Kazemi Arababadi
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

2.  Establishing the link between hepatitis B virus infection and colorectal adenoma.

Authors:  Brijesh B Patel; Seth Lipka; Huafeng Shen; Ashley H Davis-Yadley; Prakash Viswanathan
Journal:  J Gastrointest Oncol       Date:  2015-10

Review 3.  Is the CCR5 Δ 32 mutation associated with immune system-related diseases?

Authors:  Khodayar Ghorban; Maryam Dadmanesh; Gholamhossein Hassanshahi; Mohammad Momeni; Mohammad Zare-Bidaki; Mohammad Kazemi Arababadi; Derek Kennedy
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

Review 4.  Is the IL-10 promoter polymorphism at position -592 associated with immune system-related diseases?

Authors:  Mojgan Noroozi Karimabad; Mohammad Kazemi Arababadi; Elham Hakimizadeh; Hassan Yousefi Daredori; Mahmood Nazari; Gholamhossein Hassanshahi; Derek Kennedy
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

5.  Loss of expression of MHC class I-related chain A (MICA) is a frequent event and predicts poor survival in patients with hepatocellular carcinoma.

Authors:  Jie Zhang; Zhuding Xu; Xingchun Zhou; Haibin Zhang; Ning Yang; Yousheng Wu; Yibing Chen; Guangshun Yang; Tingting Ren
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

Review 6.  TLR3 plays significant roles against hepatitis B virus.

Authors:  Masoud Karimi-Googheri; Mohammad Kazemi Arababadi
Journal:  Mol Biol Rep       Date:  2014-01-30       Impact factor: 2.316

7.  Ectopic expression of micro-RNA-1, 21 and 125a in peripheral blood immune cells is associated with chronic HBV infection.

Authors:  Mohammad Momeni; Gholamhossein Hassanshahi; Mohammad Kazemi Arababadi; Derek Kennedy
Journal:  Mol Biol Rep       Date:  2014-04-16       Impact factor: 2.316

8.  Clinical significance of occult hepatitis B infection in progression of liver disease and carcinogenesis.

Authors:  Hiroki Nishikawa; Yukio Osaki
Journal:  J Cancer       Date:  2013-07-11       Impact factor: 4.207

9.  High Serum Levels of TGF-β in Iranians With Chronic HBV Infection.

Authors:  Hossein Khorramdelazad; Gholamhossein Hassanshahi; Behzad Nasiri Ahmadabadi; Mohammad Kazemi Arababadi
Journal:  Hepat Mon       Date:  2012-11-05       Impact factor: 0.660

10.  Association of cord blood levels of IL-17A, but not TGF-β with pre-term neonate.

Authors:  Masoud Mobini; Sakineh Mirzaie; Hossein Khorramdelazad; Nahid Zainodini; Zahra Sabzali; Mina Ghyasi; Mitra Mokhtari; Reza Bahramabadi; Hamid Hakimi; Khodayar Ghorban; Maryam Dadmanesh; Vahid Ehsani; Mohammad Kazemi Arababadi
Journal:  Iran J Reprod Med       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.